April 28th 2023
Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.
Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.
April 21st 2023
A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.
Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.
April 14th 2023
In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.
A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.
April 7th 2023
Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.
Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.
January 27th 2022
Gerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.
Gerald Prager, MD, leads the discussion on sequencing strategies for patients with relapsed mCRC, including those not previously treated with anti-EGFR inhibitors.
Gerald Prager, MD, and Chiara Cremolini, MD, PhD, share their approach to managing the case of a 72-year-old man with mCRC disease progression and provide insight on rechallenging patients with anti-EGFR regimens.
Chiara Cremolini, MD, PhD, discusses dosing strategies and the optimal management of adverse events with regorafenib for patients with mCRC.
Experts in gastrointestinal cancers explore treatment approaches, such as with regorafenib, in patients with mCRC who have progressed on chemotherapy/anti-EGFR therapy.
Chiara Cremolini, MD, PhD; Gerald Prager, MD; and Tanios S. Bekaii-Saab, MD, share their approach to maintenance therapy, including with EGFR inhibitors, for the management of advanced CRC.
Chiara Cremolini, MD, PhD, leads the discussion on the advantage of treating MSI-high metastatic colorectal cancer with immune checkpoint inhibitors.
Tanios S. Bekaii-Saab, MD, presents the case of a 65-year-old woman with stage IV adenocarcinoma of the rectum, and the panel reviews frontline treatment options for a patient with newly diagnosed mCRC.
November 30th 2021
Experts in gastrointestinal cancers review the role of genomic testing in metastatic colorectal cancer and its impact on informing treatment decisions.
Tanios S. Bekaii-Saab, MD, Gerald Prager, MD, and Chiara Cremolini, MD, PhD, provide insight on the treatment landscape and international screening guidelines of colorectal cancer.
April 16th 2021
Considerations for treating BRAF-mutated metastatic colorectal cancer with the combination of a BRAF inhibitor plus anti-EGFR agent based on recently presented data.
The role of molecular assays, including liquid biopsies, in providing information on resistance mechanisms in metastatic colorectal cancer and the impact of testing results on decisions for rechallenging with a previous therapy.